InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,634.80
(
0.80%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
86.83
(
-0.10%
)
Bitcoin
60,172.40
(
0.01%
)
Post# of 252477
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

biomaven0

Send PM Follow Ignore
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

biomaven0

Re: DewDiligence post# 205293

Monday, 10/17/2016 4:36:41 PM

Monday, October 17, 2016 4:36:41 PM

Post# of 252477
>>CMX157 and TAF have the same active ingredient (tenofovir), and both requires a much lower dose than Viread to generate Viread-equivalent efficacy.

From what I know (which admittedly isn't much) the CMX drug concentrates in the liver. So they have at least a shot at a better therapeutic ratio for HBV.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up